July 14, 2010
Aptium Oncology’s Research Department featured two consortia at the recent ASCO 2010 Annual Meeting in Chicago which was aptly themed ‘Advancing Quality through Innovation.’ More than 30,000 cancer specialists from around the world gather at this premier meeting annually to discuss the latest innovations in research, quality, practice and technology in cancer.
The Aptium Oncology GI Cancer Consortium (AGICC) and the newly launched Aptium Oncology Myeloma Consortium (AMyC) drew the attention of industry sponsors interested in collaborating with the consortia on clinical trials for the development of compounds targeted to GI cancers and myeloma.
A new booth design highlighted the consortia’s value proposition and featured the names of the renowned investigators and institutions involved with the consortia. In addition, the research team led by Marti McKinley, Aptium’s VP of Clinical Research, hosted a reception which allowed consortia members to discuss the distinct features and benefits of AGICC and AMyC with potential sponsors.
Currently, AGICC is recruiting patients for three trials in colorectal and pancreas cancer, while AMyC has two trials in the protocol development stage for myeloma, which are slated to start up later in the year. AGICC is directed by Dr. Lawrence Leichman, Consortium Medical Director, Aptium Oncology, and medical oncologist at the Comprehensive Cancer Center at Desert Regional Medical Center in Palm Springs. Dr. Brian G.M. Durie, co-founder and chair of the International Myeloma Foundation (IMF), heads the AMyC consortium.
About AGICC and AMyC
The Aptium Oncology GI Cancer Consortium and Aptium Oncology Myeloma Consortium provide expertise and innovative solutions for the rapid start-up and completion of complex cancer trials with translational endpoints. These consortia bring together the highest quality institutions and pharmaceutical sponsors to use the best possible data in the fastest way possible, to facilitate and speed the decision-making process in drug development.